Dataset

This dataset was created by Pooja Das

Contents

Dataset

This dataset was created by Amir Mohammad Parvizi

Released under MIT

Contents

Snapshot img

Thyroid Gland Disorder Treatment Market Size 2024-2028

The thyroid gland disorder treatment market size is forecast to increase by USD 848.5 million at a CAGR of 5.01% between 2023 and 2028. The thyroid gland disorder market is experiencing significant growth due to increasing awareness programs for thyroid treatments worldwide. The focus on emerging economies, where the prevalence of thyroid disorders is high, is also driving market expansion. However, the high entry barriers set by established players pose a challenge for new entrants. Homecare testing kits have gained popularity in recent years, enabling patients to monitor their thyroid function from the comfort of their homes. Medical research and advancements in medical technology continue to provide new treatment options for conditions such as hyperthyroidism and hypothyroidism. Iodine deficiency remains a major cause of thyroid disorders, making it essential for governments and healthcare organizations to implement prevention programs. Overall, the market is expected to continue growing as more effective treatments and diagnostic tools become available.

Request Free Sample

The thyroid gland plays a crucial role in maintaining the body's metabolic processes. Thyroid gland disorders, including hyperthyroidism and hypothyroidism, affect millions of Americans, particularly those in the geriatric demographic. The prevalence of these conditions is attributed to various factors, including aging populations and iodine deficiency. Medical technology continues to evolve, offering innovative solutions for the diagnosis and treatment of thyroid gland disorders. Customized medicine techniques and novel medicines are gaining traction, enabling healthcare providers to offer personalized care. Telemedicine and remote monitoring solutions are also becoming increasingly popular, providing patients with easy access to endocrinology consultations and thyroid function tests.

Furthermore, diagnostic technologies have advanced significantly, with ultrasound imaging and thyroid function tests being the most common methods for identifying thyroid disorders. Thyroid function tests measure the levels of thyroid hormones in the blood, while ultrasound imaging provides visualization of the thyroid gland. These diagnostic methods enable early detection and effective treatment of thyroid conditions, such as Hashimoto's thyroiditis, euthyroid sick syndrome, subacute thyroiditis, and thyroid cancer. Hyperthyroidism, characterized by an overactive thyroid gland, can lead to symptoms such as weight loss, anxiety, and rapid heartbeat. Hypothyroidism, on the other hand, results from an underactive thyroid gland and can cause symptoms such as fatigue, weight gain, and depression.

Moreover, treatment for these conditions includes medications such as thyroxin, which replaces or provides more thyroid hormone, and iodine supplements for those with iodine deficiency. The market for thyroid gland disorder treatment in the US is expected to grow due to the increasing prevalence of these conditions and the development of new technologies and treatments. The use of telemedicine and remote monitoring solutions is expected to increase, providing patients with greater access to care and enabling healthcare providers to offer more personalized treatment plans. In conclusion, the market in the US is experiencing significant growth due to the increasing prevalence of these conditions and the development of new technologies and treatments.

Furthermore, diagnostic technologies, such as ultrasound imaging and thyroid function tests, are essential for early detection and effective treatment. Customized medicine techniques and novel medicines, along with telemedicine and remote monitoring solutions, are enabling healthcare providers to offer personalized care and greater access to treatment for patients with thyroid gland disorders.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Hypothyroidism
  Hyperthyroidism


Distribution Channel

  Offline
  Online


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Type Insights

The hypothyroidism segment is estimated to witness significant growth during the forecast period. Hypothyroidism, also known as an underactive thyroid condition, occurs when the thyroid gland fails to produce sufficient thyroid hormones. This disorder, affecting an estimated 200 million people worldwide according to the Thyroid Foundation of Canada, often goes unnoticed during its early stages. However, if left untreated, it can lead to a range of health complications, including obesity, infertility, joint pain, an

Thyroid Disorder Treatment Market size was valued at USD 2.29 Billion in 2023 and is projected to reach USD 3.1 Billion by 2030, growing at a CAGR of 3.9% during the forecast period 2024-2030.
Global Thyroid Disorder Treatment Market Drivers

The market drivers for the Thyroid Disorder Treatment Market can be influenced by various factors. These may include:

Thyroid Disorder Prevalence: There is an increasing need for efficient therapies as the incidence and prevalence of thyroid disorders, including hyperthyroidism, hypothyroidism, thyroid nodules, and thyroid cancer, continue to rise worldwide.
Developments in Diagnostic Technologies: The need for treatments is fueled by the early and accurate diagnosis of thyroid problems made possible by technological breakthroughs in diagnostic instruments including ultrasound, blood tests (TSH, T3, T4), and fine-needle aspiration biopsy methods.
Growing Awareness and Screening Programs: Government-sponsored screening programs, educational initiatives, and awareness campaigns are increasing public knowledge of thyroid problems, which will help with early diagnosis and treatment and consequently propel market expansion.
Increasing Geriatric Population: Thyroid diseases are more common in older persons due to global population aging. The market for treatments for thyroid disorders is expanding in part due to the aging population.
Environmental Factors and Lifestyle Changes: A number of factors, including exposure to environmental contaminants, dietary choices, elevated stress levels, and altered lifestyles, are linked to the increasing prevalence of thyroid problems and the need for therapy.
Technological Advances in Treatment Modalities: More effective and individualized treatment options are made possible by developments in thyroid hormone replacement therapy, radioactive iodine therapy, thyroidectomy, minimally invasive surgeries, and targeted therapies. This has led to a growth in the market.
Government Initiatives and Healthcare Reforms: Market growth is positively impacted by government initiatives to enhance the healthcare system, provide access to healthcare services, and establish reimbursement guidelines for treatments of thyroid disorders.
Growing Healthcare Expenditure: People can now afford thyroid disease treatments and diagnostic tests because to rising healthcare spending, particularly in emerging nations. This helps the market grow.
Strategic Partnerships and Collaborations: The discovery of innovative medications and treatments for thyroid problems is the driving force behind market expansion in partnerships and collaborations between pharmaceutical companies, research centers, and healthcare organizations.
Growing Need for Generic Pharmaceuticals: The market is growing in part due to the rising need, particularly in emerging nations, for affordable treatment choices like generic pharmaceuticals.

As per the results of a large scale survey conducted across India in 2021, about 13 percent of the respondents above 60 years of age suffered from thyroid problems. Whereas around five percent of the respondents below 19 years of age reported to have thyroid issues.

Thyroid Disorder Market Outlook

The global thyroid disorder market size was valued at approximately $2.5 billion in 2023 and is projected to reach around $4.7 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period. This growth is largely driven by the increasing prevalence of thyroid disorders worldwide, which necessitates the need for effective diagnostic and treatment options.

One of the primary growth factors for the thyroid disorder market is the rising incidence of thyroid diseases, such as hypothyroidism, hyperthyroidism, and thyroid cancer. According to various health organizations, the number of people suffering from thyroid disorders has been steadily increasing, which is attributed to factors such as aging populations, exposure to environmental pollutants, and genetic predispositions. This surge in the patient population is creating a robust demand for diagnostic and therapeutic solutions, thereby propelling the market forward.

Advancements in medical technology and pharmaceuticals are also significantly contributing to market growth. Innovations in diagnostic tools, such as high-resolution imaging and sensitive blood tests, are enabling earlier and more accurate detection of thyroid disorders. Additionally, the development of new medications and targeted therapies is enhancing treatment efficacy and patient outcomes. These technological advancements are making it possible to manage thyroid disorders more effectively, thus driving market expansion.

The growing awareness about thyroid health is another crucial growth factor. Public health initiatives and awareness campaigns are educating people about the importance of thyroid health, the symptoms of thyroid disorders, and the available treatment options. This increased awareness is leading to higher diagnostic rates and prompt treatment, thereby reducing disease burden and improving quality of life for patients. Moreover, the rise of telemedicine and online consultations has made it easier for patients to access medical advice and treatment, further boosting market growth.

Disorder Type Analysis

Hypothyroidism is one of the most common thyroid disorders, characterized by an underactive thyroid gland that does not produce enough thyroid hormones. The segment accounted for the largest share of the market in 2023 and is expected to maintain its dominance throughout the forecast period. The high prevalence of hypothyroidism, coupled with the availability of effective treatment options, such as synthetic thyroid hormones, is driving this segment's growth. Additionally, ongoing research into more efficient and patient-friendly treatments is likely to further boost the segment.

Hyperthyroidism, characterized by an overactive thyroid gland, is another significant segment within the thyroid disorder market. Although less common than hypothyroidism, hyperthyroidism can lead to severe health complications if left untreated. The segment is expected to grow at a steady rate due to the increasing awareness about the condition and the availability of various treatment options, such as anti-thyroid medications and radioactive iodine therapy. Newer treatment modalities and improved diagnostic techniques are also contributing to the segment's growth.

Thyroid cancer represents a smaller but rapidly growing segment within the thyroid disorder market. The incidence of thyroid cancer has been rising globally, driven by factors such as increased diagnostic scrutiny and genetic predispositions. The development of targeted therapies and advanced surgical techniques is significantly improving patient outcomes, thereby driving the growth of this segment. Additionally, ongoing research into the molecular mechanisms of thyroid cancer is opening new avenues for treatment, further enhancing the segment's prospects.

Other thyroid disorders, including goiter and thyroiditis, also constitute a notable segment of the market. Although these conditions are less common, they can lead to significant health issues if not properly managed. The availability of various diagnostic and treatment options, coupled with increasing awareness about these conditions, is driving the growth of this segment. Moreover, ongoing research into the causes and treatment of these disorders is likely to contribute to the segment's expansion.

Report Scope

ABSTRACT Objective In this study, we aimed to describe the prevalence and distribution of positive antithyroperoxidase antibodies (TPOAb) according to sex, age strata, and presence of thyroid dysfunction using baseline data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Materials and methods Thyroid hormone tests were obtained from each study participant at baseline. Levels of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) were measured using a third-generation immunoenzymatic assay. Antithyroperoxidase antibodies were measured by electrochemiluminescence and were considered to be positive when ≥ 34 IU/mL. Results The prevalence of TPOAb among 13,503 study participants was 12%. Of participants with positive TPOAb, 69% were women. Almost 60% of the individuals with positive TPOAb were white. The presence of positive TPOAb was associated with the entire spectrum of thyroid diseases among women, but only with overt hyperthyroidism and overt hypothyroidism in men. Conclusion The distribution of positive TPOAb across sex, race, age, and thyroid function in the ELSA-Brasil study is aligned with the worldwide prevalence of positive TPOAb reported in iodine-sufficient areas. In women, the presence of TPOAb was related to the entire spectrum of thyroid dysfunction, while in men, it was only related to the occurrence of overt thyroid disease.

Thyroid Function Test Market Outlook

The global thyroid function test market was valued at approximately $1.2 billion in 2023 and is projected to reach around $2.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. The market size is primarily driven by the increasing prevalence of thyroid diseases, rising awareness about thyroid disorders, and advances in diagnostic technologies. The high incidence of conditions like hypothyroidism and hyperthyroidism among the global population is a significant growth factor for this market.

One of the major growth factors for the thyroid function test market is the rising awareness and increasing diagnostic rates of thyroid disorders. As healthcare systems around the world become more advanced and accessible, more individuals are being diagnosed with thyroid conditions at earlier stages. This has been bolstered by public health initiatives focusing on the importance of early diagnosis and management of thyroid-related diseases. Furthermore, the rise in routine health check-ups that include thyroid function tests has contributed significantly to market growth.

Technological advancements in diagnostic tools and methods are another critical driver of market expansion. Innovations such as high-sensitivity TSH assays, point-of-care testing, and the integration of artificial intelligence in diagnostic processes have revolutionized the accuracy and speed of thyroid tests. These advancements not only improve diagnostic accuracy but also enhance patient outcomes by enabling timely and effective treatment interventions. As a result, healthcare providers are increasingly adopting these advanced technologies, which, in turn, drives market growth.

The growing geriatric population and the associated rise in the prevalence of thyroid disorders among elderly individuals is also contributing to the market's growth. Older adults are more susceptible to thyroid dysfunction, necessitating regular thyroid function tests for effective management. Additionally, the increased focus on personalized medicine and the importance of tailored treatment plans have further highlighted the need for accurate thyroid function testing, thereby propelling market demand.

Regional outlook for the thyroid function test market indicates significant growth potential in various parts of the world. North America and Europe are expected to remain dominant due to their advanced healthcare infrastructure, high awareness levels, and robust diagnostic frameworks. However, the Asia Pacific region is anticipated to witness the fastest growth during the forecast period due to the increasing healthcare expenditure, improving diagnostic facilities, and growing awareness about thyroid disorders. Latin America and the Middle East & Africa are also expected to show moderate growth, driven by rising healthcare initiatives and improving access to diagnostic services.

Test Type Analysis

The thyroid function test market can be segmented based on test types, including TSH Test, T3 Test, T4 Test, and others. The TSH (Thyroid Stimulating Hormone) Test is the most commonly used test and holds the largest market share. This is due to its high sensitivity and reliability in detecting thyroid dysfunction. TSH tests are often the first-line diagnostic tool for evaluating thyroid function and are widely recommended by healthcare professionals. The increasing prevalence of thyroid disorders and the routine use of TSH tests in screening programs contribute significantly to their market dominance.

The T3 (Triiodothyronine) Test, which measures the levels of T3 hormone in the blood, is another crucial segment. While not as commonly used as the TSH test, the T3 test is essential in diagnosing and monitoring hyperthyroidism and other thyroid-related conditions. The demand for T3 tests is driven by the need for comprehensive thyroid function assessment, especially in complex cases where TSH and T4 tests alone may not provide a complete picture. Advances in assay technologies and the increasing use of T3 tests in clinical practice are expected to drive growth in this segment.

The T4 (Thyroxine) Test measures the levels of thyroxine in the blood and is often used in conjunction with TSH tests to provide a more detailed evaluation of thyroid function. The T4 test is particularly important in diagnosing and managing hypothyroidism and hyperthyroidism. The segment is expected to grow steadily due to the rising prevalence of thyroid disorders and the increasing use of T4 tests in routine and specialized diagno

Background: Metabolic syndrome (MetS) is a cluster of risk factors associated with increased cardiovascular disease and diabetes risk. Thyroid dysfunction (TD), especially hypothyroidism, has been observed more frequently in individuals with MetS. However, the relationship between thyroid function and metabolic syndrome components remains debated. This study aimed to explore the prevalence of thyroid dysfunction and its association with metabolic syndrome components in patients.

Methods: A cross-sectional study was conducted at Sri Aurobindo Medical College & P.G. Institute, Indore. A total of 120 patients meeting the International Diabetes Federation (IDF) criteria for metabolic syndrome were included. Detailed history, anthropometric measurements, blood pressure recordings, fasting blood sugar, lipid profile, and thyroid assays were performed. Statistical analysis using SPSS22 and Excel was employed to assess thyroid dysfunction prevalence and its correlation with metabolic syndrome components.

Results: Among 120 patients with metabolic syndrome, 28% had thyroid dysfunction. Hypothyroidism was predominant, with subclinical hypothyroidism being the most common type. Females and older individuals (>45 years) showed a higher prevalence of thyroid dysfunction. Patients with thyroid dysfunction exhibited altered metabolic syndrome components, including increased waist circumference, decreased HDL-C, elevated blood pressure, fasting glucose, and triglyceride levels.

Conclusion: The study highlights a high prevalence of thyroid dysfunction, especially hypothyroidism, among patients with metabolic syndrome. These findings suggest a potential association between thyroid status and metabolic syndrome components. Screening for thyroid dysfunction in individuals with metabolic syndrome could aid in optimizing clinical management strategies. Further research with larger sample sizes and prospective designs is warranted to explore the impact of thyroid dysfunction management on metabolic syndrome outcomes.

The Thyroid Gland Disorders Treatment Market is Segmented by Type of Disorder (Hypothyroidism, Hyperthyroidism, and Other Types of Disorder), Route of Administration (Oral, Parenteral, and Other Routes of Administration), Drug Class (Thioamides, Ionic Inhibitors, Hormone-release Inhibitors, and Other Drug Classes), Distribution Channel (Wholesale Distribution, Retail Stores, and Online Pharmacy), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Thyroid diseases are common, and use of levothyroxine is increasing worldwide. We investigated the influence of gender, race and socioeconomic status on the diagnosis and treatment of thyroid disorders using data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), a multicenter cohort study of civil servants (35-74 years of age) from six Brazilian cities. Diagnosis of thyroid dysfunction was by thyrotropin (TSH), and free thyroxine (FT4) if TSH was altered, and the use of specific medications. Multivariate logistic regression models were constructed using overt hyperthyroidism/hypothyroidism and levothyroxine use as dependent variables and sociodemographic characteristics as independent variables. The frequencies of overt hyper- and hypothyroidism were 0.7 and 7.4%, respectively. Using whites as the reference ethnicity, brown, and black race were protective for overt hypothyroidism (OR=0.76, 95%CI=0.64-0.89, and OR=0.53, 95%CI=0.43-0.67, respectively, and black race was associated with overt hyperthyroidism (OR=1.82, 95%CI=1.06-3.11). Frequency of hypothyroidism treatment was higher in women, browns, highly educated participants and those with high net family incomes. After multivariate adjustment, levothyroxine use was associated with female gender (OR=6.06, 95%CI=3.19-11.49) and high net family income (OR=3.23, 95%CI=1.02-10.23). Frequency of hyperthyroidism treatment was higher in older than in younger individuals. Sociodemographic factors strongly influenced the diagnosis and treatment of thyroid disorders, including the use of levothyroxine.

Abstract:

Objectives: Thyroid dysfunction such as hypothyroidism (THO) and hyperthyroidism (THE) are the disease caused by pathological processes in the thyroid. The current diagnosis of thyroid dysfunction is variable because of ages and genders. The aim of this study was to explore the novel candidate biomarker panels for hypothyroidism and hyperthyroidism screening with mass spectrometry and bioinformatics.

Methods: Plasma samples were collected from 15 THE patients, 9 THO patients, and 15 healthy controls. DIA-based proteomic and untargeted metabolomic analyses were performed to identify the novel biomarker panels for THO and THE. Finally, three candidate biomarkers were verified by ELISA in 34 samples.

Results: A total of 2738 proteins and 6103 metabolites were identified, and 173 proteins and 2487 metabolites were found to be differentially expressed among THE, THO and control groups. The results of the ensemble feature selection, K-means clustering and the least absolute shrinkage and selection operator (LASSO) regression model showed that four proteins (C4A, C3/C5 convertase, APOL1, and ITIH4) and four metabolites (L-arginine, L-proline, cortisol, and cortisone) identified by plasma proteomics and metabolomics could help distinguish THO and THE patients from healthy controls.

Conclusions: This study identified and verified two pairs of biomarker panels that can distinguish the THE and THO patients regardless of ages and genders. Consequently, our findings represent a comprehensive analyses of thyroid dysfunction plasma, which is significant for the clinical diagnosis.

BackgroundThyroid dysfunction significantly affects the health and development of adolescents. However, comprehensive studies on its prevalence and characteristics in US adolescents are lacking.MethodsWe investigated the prevalence of thyroid dysfunction in US adolescents aged 12–18 years using data from the National Health and Nutrition Examination Survey (NHANES) 2001–2002 and 2007–2012 cycles. Thyroid dysfunction was assessed using serum thyroid-stimulating hormone (TSH) and free thyroxine (fT4) measurements. We analyzed the prevalence across demographic subgroups and identified associated risk factors.ResultsThe study included 2,182 participants, representing an estimated 12.97 million adolescents. The group had a weighted mean age of 15.1 ± 0.06 years, with males constituting 51.4%. Subclinical hyperthyroidism emerged as the most prevalent thyroid dysfunction, affecting 4.4% of the population. From 2001–2002 to 2011–2012, subclinical hyperthyroidism remained consistent at 4.99% vs. 5.13% in the overall cohort. Subclinical and overt hypothyroidism was found in 0.41 and 1.03% of adolescents respectively, and overt hyperthyroidism was rare (0.04%). The prevalence of thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) positivity in the overall population were 5.8 and 9.8%, respectively. Positivity for TgAb was risk factors for hypothyroidism, while older age, female and Black Americans were risk factors for hyperthyroidism. Female adolescents and adolescents with an older age were more likely to be positive for TPOAb and TgAb, while Black and Mexican Americans had a lower risk of TPOAb and TgAb positivity.ConclusionSubclinical hyperthyroidism was the most common form of thyroid dysfunction, and its prevalence remained stable from 2001–2002 to 2011–2012. Notable disparities in the prevalence of hyperthyroidism and antibody positivity were observed among different age, sex and racial/ethnic groups.

There have been controversies on the influence of HIV on thyroid functioning. Several studies reported increased burden of thyroid diseases amongst HIV patients. The current understanding of burden of thyroid diseases in people with HIV, particularly its prevalence and its interaction with HIV related factors (like CD4 count), is limited and fragmented across various studies. A meta-analysis of existing literature is important to provide a comprehensive understanding, identify research gaps, and suggest directions for future research on thyroid function in HIV-infected individuals.

As per the results of a large scale survey conducted across India in 2021, about 12 percent of the respondents living in Chandigarh suffered from thyroid problems. Only around five percent of respondents from Pune reported to have thyroid problems that year.

As per the results of a large scale survey conducted across India in 2021, about 7.3 percent of the respondents suffered from thyroid related problems. This was a slight fall in the share of people with thyroid issues when compared to the previous year of the survey.

Whole-exome sequencing of a cohort of families (probands and affected/unaffected relatives) suffering from one of two rare thyroid disorders: congenital hypothyroidism (CH) and resistance to thyroid hormone (RTH). . This dataset contains all the data available for this study on 2018-08-13.

As per the results of a large scale survey conducted across India in 2019, about 18 percent of the severely obese respondents suffered from thyroid problems. Whereas only eight percent of the respondents in the normal to overweight weight range reported to have thyroid problems.

Get the sample copy of Thyroid Disorder Market Report 2024 (Global Edition) which includes data such as Market Size, Share, Growth, CAGR, Forecast, Revenue, list of Thyroid Disorder Companies (Mylan, Merck KGaA, Allergan, Pfizer Inc, AbbVie Inc., GlaxoSmithKline Plc, RLC Labs), Market Segmented by Type (Hypothyroidism, Hyperthyroidism), by Application (Hospitals, Clinics, Others)